All News

Radiation Therapy Now More Targeted and Tolerable in GI Cancer

April 17th 2025, 9:00pm

Article

Radiation therapy for gastrointestinal cancers is more precise and easier to tolerate due newer technologies and personalized care, according to experts.

Dr. Grivas Highlights Three Practice-Changing Trials in Bladder Cancer

April 17th 2025, 8:00pm

Video

Dr. Petros Grivas discusses the importance of tailoring treatment decisions in bladder cancer based on data from three practice-changing phase 3 trials.

Antibody-Drug Conjugates Changed the Standard of Care in Bladder Cancer

April 17th 2025, 7:00pm

Article

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, replacing single-agent treatments.

New Jersey Patients Receiving First-of-Its-Kind Catheter Based Pancreatic Cancer Treatment

April 17th 2025, 6:13pm

Article

Experts at Hackensack Meridian Jersey Shore University Medical Center have successfully treated their first patients using the TAMP™ therapy platform.

How I Manage When My Social Media Friends with Cancer Disappear

April 17th 2025, 5:00pm

Article

I stay in the cancer social media world because it helps me cope, even when friends disappear and I’m left wondering if they’re resting, retreating or gone.

U.S. Centers Seek Namodenoson for Pancreatic Cancer Compassionate Use

April 17th 2025, 4:00pm

Article

U.S. medical centers are seeking FDA authorization for the compassionate use — or expanded access — of Namodenoson for patients with pancreatic cancer.

Emactuzumab Gets Fast Track Designation in Tenosynovial Giant Cell Tumors

April 17th 2025, 3:00pm

Article

Emactuzumab has received fast track designation from the U.S. FDA for patients with tenosynovial giant cell tumors and who would not benefit from surgery.

Raising Awareness on Multidisciplinary Approaches in GI Cancers

April 17th 2025, 1:00pm

Video

Patients with gastrointestinal cancer may benefit from multidisciplinary care and open communication with their care team, as per an expert.

FDA sBLA Submitted for Anktiva Plus BCG in Papillary Bladder Cancer

April 16th 2025, 9:00pm

Article

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

TLX101 Demonstrated Efficacy in Recurrent High-Grade Glioma

April 16th 2025, 7:00pm

Article

TLX101 therapy was efficacious in recurrent high-grade glioma, a type of brain cancer, according to preliminary results from the phase 2 IPAX-Linz study.